

1  
2  
3 **Title:** **Geographic Clustering of Emergency Department Presentations for Acute**  
4 **Coronary Syndromes and Heart Failure in Alberta, Canada: A Population-**  
5 **based Study**  
6  
7

8  
9  
10 **Short Title:** Geographic Clusters of ACS and HF

11  
12 **Authors:** Rhonda J. Rosychuk, PhD<sup>1,2</sup>; Brian H. Rowe, MD, MSc<sup>3,4,5,6</sup>; Finlay A.  
13 McAlister, MD, MSc<sup>4,6</sup>  
14  
15

16  
17 **Affiliations:**

18  
19 <sup>1</sup>Department of Pediatrics, University of Alberta, Rm 3-524, Edmonton Clinic Health  
20 Academy (ECHA), 11405 87 Avenue NW, Edmonton, Alberta T6G 1C9, Canada  
21  
22

23  
24 <sup>2</sup>Women & Children's Health Research Institute, Rm 4-081, Edmonton Clinic Health  
25 Academy (ECHA), 11405 87 Avenue NW, Edmonton, Alberta T6G 1C9, Canada  
26  
27

28  
29 <sup>3</sup>Department of Emergency Medicine, University of Alberta, 8440 112 Street Edmonton,  
30 Alberta T6G 2B7, Canada  
31  
32

33  
34 <sup>4</sup>Alberta Health Services, 10030 107 Street NW, Edmonton, Alberta, T5J 3E4, Canada  
35

36  
37 <sup>5</sup>School of Public Health, University of Alberta, 3-300 Edmonton Clinic Health Academy,  
38 11405 - 87 Avenue NW, Edmonton, Alberta, T6G 1C9, Canada  
39

40  
41 <sup>6</sup>Department of Medicine, University of Alberta, 13-103 Clinical Sciences Building, 11350  
42 83 Avenue NW, Edmonton, Alberta, T6G 2G3, Canada  
43  
44

45  
46 **Correspondence:** Rhonda J. Rosychuk, PhD  
47 Department of Pediatrics, University of Alberta  
48 11405 87 Avenue NW, Edmonton, Alberta T6G 1C9 CANADA  
49 rhonda.rosychuk@ualberta.ca  
50 1-780-492-0318  
51 orcid.org/0000-0001-8019-5466  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Contributor's Statements:**

All authors contributed substantially to conception and design, interpreted data, revised the manuscript critically for important intellectual content, gave final approval of the version to be published, and agree to act as guarantors of the work. RJR and BHR acquired the data. RJR performed the statistical analysis and created an initial manuscript draft.

**Document:**

Abstract: 217 words; Text: 2,500 words; References: 21.

Confidential

## Abstract

**Background:** Collectively, the most common acute cardiac presentations to emergency departments (EDs) are acute coronary syndromes (ACS) and heart failure (HF). We examine geographic variation and clustering in ED presentations by adults for ACS or HF in Alberta, Canada in 2010/2011.

**Methods:** All ED presentations for ACS or HF made by Alberta residents aged  $\geq 35$  years during 2010/2011 were extracted from five linked population-based administrative health databases. Data extracted included demographics, hospitalizations, and physician claims. Spatial scan tests and logistic regression analyses were performed.

**Results:** There were 6,342 ACS (mean age=65.9, 63.1% male) and 4,780 HF (mean age=76.6, 49.9% male) patients. For ACS (n=6,342), a primary cluster and two secondary clusters were identified. For HF (n=4,780), a primary and two secondary clusters were also identified. Different clusters were identified for the different conditions. While primary care physician claims, prior ED visits, and prior hospitalizations were higher for patients within the high use clusters for both diagnoses, they also exhibited fewer specialist claims in the prior two years (odds ratio [OR]=0.64, 95% confidence interval [CI]: 0.56, 0.73 for ACS and OR=0.51, 95% CI: 0.43, 0.61 for HF).

**Interpretation:** Geographic areas were identified with higher numbers of patients presenting to the ED for ACS or HF. Lower specialist access in these areas was associated with increased ED service use.

**Key Words:** Acute coronary syndromes, Emergency Medicine, Heart failure, Cluster detection

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential

## **Introduction**

The Emergency Department (ED) is often the initial point of contact with the health care system for patients with new-onset cardiac conditions or exacerbations of chronic cardiac conditions. Collectively, the most common acute cardiac presentations to the ED are acute coronary syndromes (ACS) and heart failure (HF).(1) Overall, there is a surprisingly limited literature focusing on these important conditions in the ED setting in Canada. In particular, geographic variations have not received much attention and such variation may represent greater severity of illness, lesser availability of health care resources, variation in healthcare delivery, or a combination of these factors.

The aims of this study were to examine geographic variation in presentations made by adults (age  $\geq 35$  years) to EDs in the province of Alberta, Canada for ACS and HF during 2010/2011.

## **Methods**

### **Study Design and Setting**

This study is a retrospective cohort study using population-based administrative health databases in Alberta, Canada, from April 1, 2010, to March 31, 2011.

Data were extracted from five Alberta administrative health databases: the Morbidity and Ambulatory Care Abstract Reporting (MACAR) for ED presentations, the Alberta Health Care Insurance Plan (AHCIP) cumulative registry file for population counts and demographic data, the Physician Claims File (PCF) for physician visits in non-ED settings for two years prior to the index ED presentation, the Discharge Abstract Database (DAD) for acute care hospitalizations, and Vital Statistics for death data. The MACAR database records ambulatory care visits to

1  
2  
3 government funded facilities and contributes to the National Ambulatory Care Records System  
4  
5 (NACRS).(2)  
6  
7

8  
9 Each MACAR record represents a single ED encounter, contains a unique identifier for each  
10  
11 Albertan, and charts are coded using the Canadian Enhancement of International Classification  
12  
13 of Diseases, 10th Revision (ICD-10-CA)(3) diagnostic codes..  
14  
15

### 16 17 **Study Protocol** 18

19  
20 The MACAR database has a main diagnosis field and nine (ICD-10-CA) additional fields for  
21  
22 diagnosis data. To be considered a presentation, the first diagnosis field in the MACAR database  
23  
24 had to match the diagnostic codes for ACS (I20.x, I21.x, I22, I23.82, I24.0, I24.8, I24.9, I25.0,  
25  
26 I25.1, I25.6, I25.8, I25.9) or HF (I11.0, I50.x, J81). All ED presentations during April 1, 2010, to  
27  
28 March 31, 2011, were extracted for Alberta residents aged  $\geq 35$  years who matched the case  
29  
30 definition. An ACS (HF) ED patient was defined as an individual with at least one ED  
31  
32 presentation for ACS (HF) during the study period. ED data for April 1, 2008, to March 31,  
33  
34 2010, were extracted to determine if a prior history of ED presentation for ACS or HF existed.  
35  
36 Alberta had 70 sub-regional health authorities (sRHAs, Figure 1)(4) with diverse population  
37  
38 sizes in 2003. The geographic data provided by Alberta Health were geo-coded to the 70 sRHAs  
39  
40 (numbered 1 to 70) and Alberta Health provided latitudes and longitudes for each sRHA's  
41  
42 population-based centroid.  
43  
44  
45  
46  
47

48  
49 Variables for the patients included the sex, age, socio-economic proxy, and sRHA of residence at  
50  
51 fiscal year end. The Alberta government funds health care in the province and healthcare  
52  
53 insurance premiums provided partial funding until January 1, 2009. Residents with lower  
54  
55 incomes or on social services (e.g., welfare) were eligible for premium subsidies. The subsidy  
56  
57  
58  
59  
60

1  
2  
3 level can be used as a proxy measure for socio-economic status. In addition, many First Nations  
4 individuals in Alberta have “Treaty” status based on treaties between their First Nation bands  
5 and the Canadian government,(5) resulting in full premium subsidies. Combining the categories  
6 and age, we created three mutually exclusive groups: seniors (individuals  $\geq 65$  years), subsidized  
7 adults (individuals  $< 65$  years receiving health care subsidies or who are First Nations), and non-  
8 subsidized adults (individuals  $< 65$  years who do not receive premium subsidies).  
9  
10  
11  
12  
13  
14  
15  
16

17  
18 Physician claims in the two years prior to the ED presentation were extracted. The variables were  
19 date of visit, three diagnostic codes and physician specialty. Diagnoses are coded using the  
20 International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).(6)  
21  
22 The diagnostic fields were used to determine prior histories of ACS (410.x, 411.1, 411.8, 413.x,  
23 414.0, 414.8, 414.9, V458.8) and HF (402.01, 402.11, 402.91, 428.x, 518.4). The prior visits  
24  
25 were also used to calculate the Charlson Comorbidity Index based on the Deyo ICD-9-CM  
26 coding scheme (hereafter called DCCI).(7) For each of the prior history and comorbidity  
27 variables, two or more physician claims in the previous two years were required to meet the  
28 definitions. Also, in the prior two years, the numbers of claims with a general practitioner and  
29 specialist (cardiology or internal medicine) were calculated. The DAD repository provided the  
30 dates of hospital admission for any reason in the two years prior to the ED presentation. Alberta  
31  
32 Vital Statistics provided deaths within 90 days of an ED presentation.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 The Human Research Ethics Board at the University of Alberta approved this study.  
48  
49

## 50 **Analysis**

51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 For each condition, numerical summaries (e.g., frequency, mean, standard deviation [SD],  
4 interquartile range [IQR]) and crude and sex and age-group directly standardized rates (DSRs)  
5 were calculated in R.(8)  
6  
7  
8  
9

10  
11 To identify geographic areas of excess numbers of patients presenting to the ED, we used the  
12 Kulldorff-Nagarwalla (KN) spatial scan test(9) that adjusts for the underlying population counts.  
13 It is a popular method for identifying clusters(10-14) and calculations were performed in  
14 SaTScan(15) with a space window of up to 50% of Alberta's population, sRHAs as the  
15 geographic boundaries, and sex and age-group as strata. The sRHA of residence was used for  
16 each patient and patients with missing sRHAs were not used in analyses. The spatial scan  
17 identifies a primary cluster (the most likely cluster that has the highest maximum likelihood ratio  
18 and rejects the null hypothesis of no clustering) and any secondary clusters (areas distinct from  
19 the primary cluster that have high maximum likelihood ratios that also reject the null). (9)  
20 Statistically significant ( $p$ -value<0.05) primary and secondary clusters were reported.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Multivariable logistic regression models were created for each condition to identify explanatory  
37 variables that differed for patients inside the statistically significant clusters. Age and sex were  
38 entered into the models even though detection was adjusted for age group and sex. Socio-  
39 economic proxy, comorbidity score, prior claims for comorbid conditions (i.e., COPD, diabetes,  
40 hypertension, kidney disease), prior ED history of ACS or HF, prior history of a hospitalization  
41 for any reason, prior history of a physician claim for ACS or HF, number of physician claims,  
42 and prior history of a specialist visit were all entered into the multivariable model. Odds ratios  
43 (ORs) and 95% confidence intervals (CIs) are provided.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## 55 **Results**

56  
57  
58  
59  
60



## General Trends

Overall, 13,283 ED presentations for ACS (7,059) and HF (6,224) were extracted. Most patients (84.8%) had 1 ED presentation and 198 were identified in both cohorts. Two patients without sRHA data were removed. Analyses were conducted on 6,342 ACS and 4,780 HF patients.

The ACS group had more males, was younger, had fewer hospitalizations, had fewer physician claims, and fewer had had a prior specialist visit than the HF group (Table 1). Within 90 days of the ED presentation, 340 (5.4%) and 821 (17.2%) patients had died in the ACS and HF groups, respectively. Overall, the crude rates of patients with at least one ED presentation were 3.25 per 1,000 (95% CI: 3.17, 3.33) for ACS and 2.45 per 1,000 (95% CI: 2.38, 2.52) for HF. When adjusted by age group and sex, the DSRs ranged from 1.67 per 1,000 (95% CI: 1.27, 2.15) to 7.98 per 1,000 (95% CI 4.63, 15.10) for ACS (Figure 2). For HF (Figure 3), the lowest DSRs ranged from 0.68 per 1,000 (95% CI: 0.36, 1.18) to 6.79 per 1,000 (95% CI: 5.16, 8.96). The regions with the highest and lowest DSRs were different for ACS and HF.

## Geographical Clustering

### *ACS*

Clusters of higher numbers of patients presenting to the ED for ACS than expected were identified (Table 2, Figure 4) in the northwest (Cluster 1, the primary cluster), east central (Cluster 2) and south (Cluster 3). Cluster 1 had 926 observed patients when 619.43 were expected, adjusted for the age group and sex distribution. With an observed to expected ratio of 1.49 and a relative risk of 1.58, this collection of sRHA's was the most likely cluster ( $p < 0.001$ ). Clusters 2 and 3 had relative risks of 1.76 ( $p < 0.001$ ) and 1.47 ( $p < 0.001$ ), respectively.

1  
2  
3 When the primary and secondary clusters were combined, variables differed for the patients  
4 residing inside versus outside the clusters (Table 3). The clusters were less likely to have non-  
5 subsidized adults (OR=0.74, 95% CI: 0.61, 0.91) and more likely to have patients with prior  
6 hospitalization (OR=1.44, 95% CI: 1.24, 1.68) or ED presentation (OR=1.29, 95% CI: 1.04,  
7 1.59) for ACS. They were less likely to have had a prior specialist claim (OR=0.64, 95% CI:  
8 0.56, 0.73), had fewer specialist claims (OR=0.97 per claim, 95% CI: 0.96, 0.98) and more  
9 general practitioner claims (OR=1.01 per claim, 95% CI: 1.01, 1.01) than patients outside the  
10 clusters. Notably, 49.5% had a specialist visit in the prior two years in the clusters compared to  
11 57.9% outside the clusters (Supplementary Table S1). Further, 8.9% of patients in the primary  
12 cluster (82/926) had at least one ED presentation that ended in admission compared to 14.0%  
13 (176/1260) and 13.2% (547/4156) in the secondary clusters and the rest of the province,  
14 respectively.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 *HF*

33  
34  
35 The primary cluster of HF patients identified included several of the areas that were part of the  
36 primary cluster for ACS as well as the northeastern part of the province (Table 2). With 677  
37 observed patients, the observed to expected ratio was 1.70 and the relative risk was 1.81  
38 (p<0.001). The first secondary cluster (Cluster 2) included two sRHAs that were part of Cluster 3  
39 for ACS. This south east portion of the province (Figure 5) had a relative risk of 1.77 (p<0.001)  
40 and Cluster 3 in eastern Alberta had a relative risk of 1.39 (p<0.003).  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 When adjusted by other factors, the patients in the clusters were less likely to be female  
52 (OR=0.82, 95% CI: 0.71, 0.94) and more likely to have a history of ACS (OR=1.34, 95% CI:  
53 1.12, 1.60). Patients in the clusters were more likely to have had a prior hospitalization  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (OR=1.44, 95% CI: 1.21, 1.71), more likely to have had a prior ED presentation for ACS  
4  
5 (OR=1.49, 95% CI: 1.15, 1.92), more likely to have had a prior ED presentation for HF  
6  
7  
8 (OR=1.41, 95% CI: 1.16, 1.71), and less likely to have had a prior specialist visit (OR=0.51,  
9  
10 95% CI: 0.43, 0.61). These patients also had more physician claims (OR=1.004 per claim, 95%  
11  
12 CI: 1.002, 1.006) and had fewer specialist claims (OR=0.98 per claim, 95% CI: 0.97, 0.98).  
13  
14 Inside the clusters, 61.2% had had a specialist visit in the two years prior compared to 72.8%  
15  
16 outside the clusters (Supplementary Table S2).  
17  
18  
19

## 20 21 **Interpretation**

22  
23  
24 Using databases involving ACS (n=6,342) and HF (n=4,780) patients, important geographic  
25  
26 variations were identified. Interestingly, different clusters for ACS and HF were identified, with  
27  
28 only some sRHAs part of the clusters for both conditions. Since the risk factors for both  
29  
30 conditions are similar, this finding would argue against regional differences in underlying risk  
31  
32 factor distributions. Similarly, specialist access would be the same for both conditions in a  
33  
34 geographic area. The clusters may exist because of a greater severity of disease, differences in  
35  
36 ED management, or a lack of available non-ED health services.  
37  
38  
39

40  
41 Few studies have examined geographic clustering for cardiac and cardiovascular conditions. In  
42  
43 2010/2011, we identified clusters of patients presenting to the ED for atrial fibrillation and flutter  
44  
45 in several sRHAs as well as clusters of these patients with a subsequent stroke or heart failure  
46  
47 physician claims.(16) We used a different statistical cluster detection method and showed that  
48  
49 most of the northern, some of the western, and some of the southern sRHA's were clusters alone  
50  
51 or in combination with neighbours. van Rhee and colleagues(12) used the spatial scan and  
52  
53 dissemination areas to identify regional variation in ischemic stroke, transient ischemic attack,  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 intracerebral hemorrhage, and subarachnoid hemorrhage, and in-hospital mortality for Alberta  
4 individuals diagnosed with stroke who accessed the health care system (e.g., hospitalizations,  
5 ambulatory care including ED visits) during 2002 to 2008. They found that clusters for different  
6 conditions did not overlap. Other cluster detection studies using Alberta data have focused on  
7 different conditions. While geographic variation in admission rates or length of stay have been  
8 identified in multiple studies for ambulatory care sensitive conditions,(17) many studies do not  
9 conduct statistical cluster detection tests or consider ED visits.  
10  
11  
12  
13  
14  
15  
16  
17  
18

19  
20 This study also revealed important differences in the characteristics of patients residing inside  
21 and outside the clusters, adjusting for other variables. As expected, most of the health services  
22 usage characteristics (prior hospitalization, ED presentation, physician claims) were higher for  
23 patients residing in the clusters and these effects are likely indicative of sicker patients who see  
24 their general practitioner's more frequently and may end up presenting to the ED or admitted to  
25 hospital as they become sicker. However, the fact that patients in the cluster were less likely to  
26 have had a prior specialist claim and had fewer specialist claims is surprising if the patients are  
27 truly sicker. This result suggests that access to specialists may be reduced in some areas and  
28 gives rise to the hypothesis that earlier specialist intervention may reduce future ED  
29 presentations. Certainly, a prior natural experiment conducted in Alberta demonstrated that  
30 increasing access to specialist care for HF patients after hospital discharge was associated with  
31 statistically significant declines in rates of mortality and readmission in the first 30 days after  
32 discharge.(18) In Quebec, the association between affiliation with a specialist and ED use  
33 depended on patient age: the <65 year group had lower ED use whilst older patients had higher  
34 ED use and patients without a primary physician had more ED use than patients with a specialist  
35 primary physician.(19) While this study involved a large number of patients, the authors did not  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 examine specific conditions or specialities. Results from different health care systems may not be  
4  
5 able to inform policy locally.(20)  
6  
7  
8  
9

10  
11 Study limitations include the case definition may not be representative of all patients who have  
12 ACS or HF. The prior histories and comorbidities may not perfectly identify patients. For  
13  
14 example, the recommendation for identifying patients with hypertension is “2 claims within two  
15  
16 years or 1 hospitalization”;(21) however, the data extract did not include admitting diagnosis.  
17  
18  
19

20  
21 Proxies for SES (e.g., Aboriginal status, subsidy) may be neither sensitive nor specific.  
22  
23

24 Aboriginal status includes only treaty First Nations and Inuit peoples and under-estimates  
25  
26 indigenous peoples, since Métis and non-treaty First Nations Albertans are excluded. Finally,  
27  
28 these databases do not provide treatment details, so clinician adherence to evidence-based  
29  
30 management guidelines and patient adherence to such treatment, as well as characteristics like  
31  
32 smoking history, cannot be determined. Nonetheless, we do not feel that these limitations have  
33  
34 had a substantial effect on our findings.  
35  
36  
37

38  
39 In conclusion, this study showed geographic variations based on the number of people presenting  
40  
41 to EDs for ACS or HF which was not explained by differences in demographics or  
42  
43 comorbidities, but patients in the high cluster areas did exhibit lower rates of prior contact with  
44  
45 specialist physicians. We hypothesize that increasing specialist access may reduce the reliance  
46  
47 on ED services in high cluster areas, although this is a hypothesis that should be tested  
48  
49 empirically.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Acknowledgements**

The authors thank Alberta Health for providing the data.

## **Funding Sources**

This work was partially supported by Alberta Health (AHW FP12-784). Dr. Rosychuk was supported by a salary award from Alberta Innovates-Health Solutions (AIHS, Edmonton, Canada; formerly the Alberta Heritage Foundation for Medical Research) as a Health Scholar. Dr. Rowe's research is supported by a Tier 1 Canada Research Chair in Evidence-based Emergency Medicine (Canadian Institutes of Health Research, Ottawa, Canada). Dr. McAlister receives salary support from AIHS and the University of Alberta Chair in Cardiovascular Outcomes Research.

## **Disclosures**

This study is based in part on data provided by Alberta Health. The interpretation and conclusions are contained herein are those of the researchers and do not necessarily represent the views of the Government of Alberta. Neither the government nor Alberta Health expresses any opinion in relation to this study.

## References

1. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital and Health Statistics Series 13, Data from the National Health Survey. 2011;159:1-38.
2. Canadian Institute for Health Information. National Ambulatory Care Reporting System (NACRS). Ottawa, ON: Canadian Institute for Health Information, 2014.
3. Canadian Institute of Health Information. The Canadian Enhancement of ICD-10 (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision). Ottawa, ON: Canadian Institute of Health Information, 2001.
4. Ellehoj E, Schopflocher D. Calculating Small Area Analysis: Definition of Sub-regional Geographic Units in Alberta. Edmonton, Alberta: Alberta Health and Wellness, 2003.
5. Aboriginal Affairs and Northern Development Canada. Terminology 2012 March 30, 2015. Available from: <http://www.aadnc-aandc.gc.ca/eng/1100100014642/1100100014643>.
6. Practice Management Information Corporation. International Classification of Diseases, 9th revision, 3rd edn, Clinical Modification. Los Angeles, CA: Practice Management Information Corporation; 1989.
7. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology. 1992;45(6):613-9.
8. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
9. Kulldorff M. A spatial scan statistic. Statistics in Medicine. 1997;26:1481-96.
10. Sasson C, Cudnik MT, Nassel A, Semple H, Magid DJ, Sayre M, et al. Identifying High-risk Geographic Areas for Cardiac Arrest Using Three Methods for Cluster Analysis. Academic Emergency Medicine. 2012;19(2):139-46.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
11. Pedigo A, Aldrich T, Odoi A. Neighborhood disparities in stroke and myocardial infarction mortality: a GIS and spatial scan statistics approach. *BMC Public Health*. 2011;11:644.
12. van Rheenen S, Watson TWJ, Alexander S, Hill MD. An Analysis of Spatial Clustering of Stroke Types, In-hospital Mortality, and Reported Risk Factors in Alberta, Canada, Using Geographic Information Systems. *Canadian Journal of Neurological Sciences*. 2015;42(05):299-309.
13. Root ED, Gonzales L, Persse DE, Hinchey PR, McNally B, Sasson C. A tale of two cities: The role of neighborhood socioeconomic status in spatial clustering of bystander CPR in Austin and Houston. *Resuscitation*. 2013;84(6):752-9.
14. Wang Z, Du Q, Liang S, Nie K, Lin D-n, Chen Y, et al. Analysis of the Spatial Variation of Hospitalization Admissions for Hypertension Disease in Shenzhen, China. *International Journal of Environmental Research and Public Health*. 2014;11(1):713-33.
15. Kulldorff M, Information Management Services Inc. SaTScan™ v9.2: Software for the spatial and space-time scan statistics. [www.satscan.org](http://www.satscan.org); 2013. p. [www.satscan.org](http://www.satscan.org).
16. Rosychuk RJ, Mariathas HH, Graham MM, Holroyd BR, Rowe BH. Geographic Clustering of Emergency Department Presentations for Atrial Fibrillation and Flutter in Alberta, Canada. *Academic Emergency Medicine*. 2015;22(8):965-75.
17. Busby J, Purdy S, Hollingworth W. A systematic review of the magnitude and cause of geographic variation in unplanned hospital admission rates and length of stay for ambulatory care sensitive conditions. *BMC Health Services Research*. 2015;15:324.



- 1  
2  
3 18. McAlister FA, Bakal JA, Kaul P, Quan H, Blackadar R, Johnstone D, et al. Changes in  
4 heart failure outcomes after a province-wide change in health service provision a natural  
5 experiment in Alberta, Canada. *Circulation: Heart Failure*. 2013;6(1):76-82.  
6  
7  
8  
9  
10 19. McCusker J, Tousignant P, Silva RBD, Ciampi A, Lévesque J-F, Vadeboncoeur A, et al.  
11 Factors predicting patient use of the emergency department: a retrospective cohort study.  
12 *Canadian Medical Association Journal*. 2012;184(6):E307-E16.  
13  
14  
15  
16  
17 20. Huntley A, Lasserson D, Wye L, Morris R, Checkland K, England H, et al. Which  
18 features of primary care affect unscheduled secondary care use? A systematic review. *BMJ*  
19 *Open*. 2014;4(5).  
20  
21  
22  
23  
24 21. Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, et al. Validation of a  
25 case definition to define hypertension using administrative data. *Hypertension*. 2009;54(6):1423-  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Tables**

Table 1: Patients and population by condition and characteristics for 2010/2011.

	ACS		HF		Population $\geq$ 35	
	n	(%)	n	(%)	n	(%)
	6,344		4,780		1,953,830	
Sex						
Female	2,340	(36.9)	2,393	(50.1)	983,570	(50.3)
Male	4,002	(63.1)	2,387	(49.9)	970,260	(49.7)
Age						
mean (SD)	65.9	(13.7)	76.6	(12.3)	54.1	(13.4)
median [IQR]	65	[77-55]	79	[86-69]	52	[62-43]
Socio-economic proxy						
Non-subsidized Adults	2,390	(37.7)	497	(10.4)	1,373,349	(70.3)
Subsidized Adults	704	(11.1)	349	(7.3)	169,665	(8.7)
Seniors	3,248	(51.2)	3,934	(82.3)	410,816	(21.0)
Comorbidity Score (based on $\geq$ 2 Physician Claims in Prior 2 Years)						
mean (SD)	1.1	(1.5)	2.3	(1.9)		
median [IQR]	1	[2-0]	2	[3-1]		
$\geq$ 2 Physician Claims in Prior 2 Years for						
COPD	1,009	(15.9)	1,669	(34.9)		
Diabetes	1,429	(22.5)	1,620	(33.9)		
Hypertension	3,270	(51.6)	2,950	(61.7)		
Kidney Disease	377	(5.9)	790	(16.5)		
ACS	2,212	(34.9)	1,570	(32.8)		
HF	788	(12.4)	2,573	(53.8)		
Hospitalization in Prior 2 Years	2,012	(31.7)	2,803	(58.6)		
ED Presentation for ACS in Prior 2 Years	602	(9.5)	399	(8.3)		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

ED Presentation for HF in Prior 2 Years	247	(3.9)	885	(18.5)
Number of GP Claims in Prior 2 Years				
mean (SD)	18.8	(24.0)	38.3	(39.5)
median [IQR]	11	[23-5]	26	[52-11]
Specialist Claim in Prior 2 Years	3,487	(55.0)	3,343	(69.9)
Number of Specialist Claims in Prior 2 Years				
mean (SD)	6.0	(12.6)	10.8	(18.5)
median [IQR]	1	[7-0]	3	[13-0]

Confidential

Table 2: Clusters identified.

	ACS	HF
Cluster 1 (primary)		
sRHA IDs	27, 28, 53, 56, 59, 60, 63, 64, 65, 66	60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70
Population	190,646	189,630
Observed Patients	926	677
Expected Patients	619.43	399.32
Observed/Expected	1.49	1.70
Relative Risk	1.58	1.81
p	<0.001	<0.001
Cluster 2 (secondary)		
sRHA IDs	35, 36, 38, 39, 40, 55	6, 7
Population	67,596	58,865
Observed Patients	441	298
Expected Patients	257.67	173.29
Observed/Expected	1.71	1.72
Relative Risk	1.76	1.77
p	<0.001	<0.001
Cluster 3 (secondary)		
sRHA IDs	1, 2, 3, 4, 5, 6, 7, 25	34, 35, 38, 39
Population	158,290	45,904
Observed Patients	819	212
Expected Patients	581.53	154.85
Observed/Expected	1.41	1.37
Relative Risk	1.47	1.39
p	<0.001	0.003


Table 3: Estimated odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regression models for the odds of being in the clusters.

	ACS		HF	
	OR	(95%CI)	OR	(95%CI)
Sex				
Female	0.87*	(0.78, 0.98)	0.82*	(0.71, 0.94)
Male	<i>Reference</i>		<i>Reference</i>	
Age	0.99	(0.99, 1.00)	0.99	(0.98, 1.00)
Socio-economic proxy				
Non-subsidized Adults	0.74*	(0.61, 0.91)	0.95	(0.69, 1.30)
Subsidized Adults	0.79	(0.63, 1.00)	0.98	(0.71, 1.37)
Seniors	<i>Reference</i>		<i>Reference</i>	
Comorbidity Score (based on $\geq 2$ Physician Claims in Prior 2 Years)	1.01	(0.95, 1.08)	1.02	(0.96, 1.09)
$\geq 2$ Physician Claims in Prior 2 Years for				
COPD	1.03	(0.87, 1.21)	1.15	(0.99, 1.35)
Diabetes	0.94	(0.81, 1.09)	0.96	(0.82, 1.13)
Hypertension	1.06	(0.95, 1.19)	1.09	(0.94, 1.26)
Kidney Disease	0.91	(0.69, 1.19)	0.81	(0.64, 1.03)
ACS	0.99	(0.86, 1.15)	1.34*	(1.12, 1.60)
HF	1.19	(0.96, 1.48)	0.99	(0.83, 1.18)
Hospitalization in Prior 2 Years	1.44*	(1.24, 1.68)	1.44*	(1.21, 1.71)
ED Presentation for ACS in Prior 2 Years	1.29*	(1.04, 1.59)	1.49*	(1.15, 1.92)
ED Presentation for HF in Prior 2 Years	1.08	(0.78, 1.50)	1.41*	(1.16, 1.71)
Number of GP Claims in in Prior 2 Years	1.01*	(1.01, 1.01)	1.00*	(1.00, 1.01)
Specialist Claim in Prior 2 Years	0.64*	(0.56, 0.73)	0.51*	(0.43, 0.61)
Number of Specialist Claims in Prior 2 Years	0.97*	(0.96, 0.98)	0.98*	(0.97, 0.98)

\* denotes  $p < 0.05$

Figures

Figure 1: Alberta's 70 sRHAs with insets for the Edmonton and Calgary areas.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 2: Age group and sex adjusted DSRs per 1,000 and 95% CIs for ACS by sRHA ID (P denotes entire province). Dotted line denotes provincial rate.





Figure 3: Age group and sex adjusted DSRs per 1,000 and 95% CIs for HF by sRHA ID (P denotes entire province). Dotted line denotes provincial rate.





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 4: ACS clusters identified. (Cluster 1 = darkest gray, Cluster 2 = dark gray, Cluster 3= medium gray)





Figure 5: HF clusters identified. (Cluster 1 = darkest gray, Cluster 2 = dark gray, Cluster 3= medium gray)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Completed
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	✓
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	✓
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	✓
Objectives	3	State specific objectives, including any prespecified hypotheses	✓
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	✓
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	✓
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	✓
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	✓
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	✓
Bias	9	Describe any efforts to address potential sources of bias	✓
Study size	10	Explain how the study size was arrived at	✓
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	✓
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	✓
		(b) Describe any methods used to examine subgroups and interactions	✓
		(c) Explain how missing data were addressed	✓
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA

Continued on next page

<b>Results</b>			<b>Completed</b>
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	✓
		(b) Give reasons for non-participation at each stage	✓
		(c) Consider use of a flow diagram	✓
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	✓
		(b) Indicate number of participants with missing data for each variable of interest	✓
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	✓
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	✓
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	✓
		(b) Report category boundaries when continuous variables were categorized	✓
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	✓
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	✓
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	✓
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	✓
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	✓
Generalisability	21	Discuss the generalisability (external validity) of the study results	✓
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	✓

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).